As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.
The Pensacola, Fla.-based company creates devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.
advertisement
There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
Criminal prosecution for violating HIPAA: an emerging threat
Next article： Drug repurposing or repositioning? The language matters
Next article： Drug repurposing or repositioning? The language matters
